DSCSA §582: GS1 DataMatrix product identifier required · EU FMD 2011/62/EU: 2D code + tamper evidence · both verify data, not the object.
In pharma the printed code is not optional and never will be: DSCSA requires the serialized GS1 DataMatrix on every package, FMD requires the 2D code plus tamper evidence in the EU. But both regimes verify data about a package, not the package itself — a well-made copy of a genuine code, on a counterfeit carton, passes a data check because the data is real. Chip-bound identity exists for exactly that residual risk: it authenticates the object, while the mandated barcode keeps satisfying the regulator.
For §582 verification, saleable returns and FMD decommissioning, the mandated 2D code and your serialization stack (TraceLink, Antares, MediLedger) are the system of record. Nothing replaces them, and any authentication layer must feed the same records.
When the question is "is this physical package the one the data describes?" — diverted product, sophisticated counterfeits with harvested serials, returns fraud — a cryptographic tap answers what a printed code structurally cannot.
| Criterion | QR / printed 2D code | NFC chip (Aeroz) |
|---|---|---|
| Required by DSCSA / FMD | Yes — mandated product identifier | No — an additional authentication layer |
| Verifies the data | Yes — serial checked against records | Yes — and binds the check to this physical unit |
| Defeats a copied genuine code | No — a copy of real data verifies as real | Yes — the chip cannot be photographed into existence |
| Saleable returns confidence | Serial matches; unit unproven | Unit proven; fraudulent returns surface at the tap |
| Patient-facing check | Requires an app and a database lookup | One tap on a phone; verdict from the unit itself |
| Integrates with serialization stack | Native | Events append via EPCIS 2.0 to the same chain of record |
This is the one industry where the comparison is genuinely additive: the DataMatrix is law, so the decision is not which carrier but whether data verification alone matches your diversion and counterfeit exposure. For most low-risk generics it does. For high-value, high-diversion products, it demonstrably has not.
Section 582 requires the product identifier — NDC, serial, lot, expiry in a GS1 DataMatrix — on each package, with unit-level electronic tracing and verification duties now in force across the chain.
EU Directive 2011/62/EU requires the unique identifier in a 2D code, verification at dispense, and an anti-tampering device — Europe's answer to the same threat model.
That the serial number exists, was issued, and has the right status in the repository. This is data verification, and it is what the law asks.
That the physical carton in hand is the one the serial was born on. Harvested genuine serials on counterfeit product pass data checks — the documented gap authentication layers exist to close.
No, and it should not try — the DataMatrix is the mandated identifier under DSCSA and the 2D code under FMD. Chip identity is an authentication layer on top, feeding the same EPCIS records.
Not necessarily. Verification confirms the data is genuine, not the object. A counterfeit carrying a copied genuine code returns a clean check — which is why verification alone under-detects sophisticated counterfeits.
High-value specialty products, cold-chain biologics, and any product with a returns-fraud or diversion history — the places where a single incident costs more than tagging the whole line.
No — §582 duties stand regardless. An Aeroz deployment appends authentication events to the same unit-level chain your serialization stack maintains, strengthening the tracing record rather than forking it.
A fixed-fee Aeroz audit maps your products, line speed and regulation against both carriers and returns a written recommendation with a scoped pilot plan, cost and timeline. $5,000 books it online; no commitment to proceed.